000 | 01112nam a22001697a 4500 | ||
---|---|---|---|
008 | 221214b2022 |||||||| |||| 00| 0 eng d | ||
020 | _a9780128206690 | ||
060 | _aWK 835 | ||
245 | 0 | _aDiabetic neuropathy | |
260 |
_aAmsterdam ; _bElsevier, _c2022 |
||
260 |
_aOxford : _bElsevier, _c2022 |
||
520 | _aThis book identifies the most accurate early biomarkers of nerve damage to better understand pathophysiology and diagnose diabetic neuropathy in the clinical care of patients, and in particular, permit an accurate evaluation of future therapies in clinical trials. This succinct reference focuses on the current data and research on diabetic neuropathy and is essential reading for researchers in endocrinology, neurology and pharmacology, along with clinicians that need to better understand the novel pathogenetic pathways leading to diabetic neuropathy and the treatments. | ||
650 | 4 |
_95867 _aDiabetic neuropathies |
|
700 | 1 | _aTavakoli, Mitra | |
856 |
_uhttps://www.clinicalkey.com/#!/browse/book/3-s2.0-C2018003978X _yBarts Health OpenAthens account holders click here for access |
||
942 | _n0 | ||
999 |
_c94064 _d94064 |